Journal of Internal Medicine Concepts & Practice >

2023 , Vol. 18 >Issue 06: 388 - 393

DOI: https://doi.org/10.16138/j.1673-6087.2023.06.003

Original article

Effect of omalizumab treatment on serum cytokine profile in allergic asthma patients

Expand
  • 1. Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    2. Department of Pulmonary and Critical Care Medicine, Zhoushan Branch of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Zhoushan 316000, China

Received date: 2023-05-16

  Online published: 2024-03-18

Fold

Abstract

Objective To investigate the effect of omalizumab on serum cytokine profile in the patients with allergic asthma. Methods A total of 20 patients with allergic asthma who received omalizumab treatment in the Department of Pulmonary and Critical Care Medicine of Ruijin Hospital were enrolled in this study. Data of spirometry test was collected before and after 4 months of omalizumab treatment to evaluate the improvement of lung function. Serum samples before and after 4 months of omalizumab treatment were collected to measure 29 cytokines using Meso Scale Discovery(MSD). Asthma control was assessed by asthma control test (ACT) score and treatment effectiveness was evaluated by the Global Evaluation of Treatment Effectiveness (GETE) score. Results After 4 months of omalizumab treatment, maximal expiratory flow at 50% of forced vital capacity (MEF50) was significantly improved among 20 patients (P<0.05). Serum interleukin(IL)-17A and IL-23 levels were significantly increased(P<0.05). Asthma control was significantly improved(P<0.01). According to GETE score, omalizumab treatment was effective in 17 patients, but not effective in 3 patients. Conclusions Omalizumab treatment effectively improves asthma control in allergic asthmatics. Increased levels of helper T17 (Th17) cell -related cytokines and recovery of Th17 cell function may be one of the potential therapeutic mechanisms of omalizumab.

Key words： Omalizumab; Allergic asthma; Cytokines

Cite this article

ZHENG Xiaoyan, SUN Lin, TANG Wei . Effect of omalizumab treatment on serum cytokine profile in allergic asthma patients[J]. Journal of Internal Medicine Concepts & Practice, 2023 , 18(06) : 388 -393 . DOI: 10.16138/j.1673-6087.2023.06.003

References

[1] Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases[J]. J Allergy Clin Immunol, 2003, 112(2):252-262.
[2] Afshar R, Medoff BD, Luster AD. Allergic asthma: a tale of many T cells[J]. Clin Exp Allergy, 2008, 38(12): 1847-1857.
[3] Palomares ó, Sánchez-Ramón S, Dávila I, et al. Divergent: how IgE axis contributes to the continuum of allergic asthma and anti-IgE therapies[J]. Int J Mol Sci, 2017, 18(6): 1328.
[4] Davis LA. Omalizumab: a novel therapy for allergic asthma[J]. Ann Pharmacother, 2004, 38(7-8): 1236-1242.
[5] Okayama Y, Matsumoto H, Odajima H, et al. Roles of omalizumab in various allergic diseases[J]. Allergol Int, 2020, 69(2): 167-177.
[6] Pelaia C, Calabrese C, Terracciano R, et al. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness[J]. Ther Adv Respir Dis, 2018, 12: 1753466618810192.
[7] Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics[J]. Eur Respir J, 2001, 18(2):254-261.
[8] 中华医学会呼吸病学分会哮喘学组. 奥马珠单抗治疗过敏性哮喘的中国专家共识(2021版)[J]. 中华结核和呼吸杂志, 2022, 45(4): 341-354.
[9] Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control[J]. J Allergy Clin Immunol, 2004, 113(1):59-65.
[10] Bousquet J, Humbert M, Gibson PG, et al. Real-world effectiveness of omalizumab in severe allergic asthma[J]. J Allergy Clin Immunol Pract, 2021, 9(7): 2702-2714.
[11] Yalcin AD, Uzun R. Anti-IgE significantly changes circulating interleukin-25, vitamin-D and interleukin-33 levels in patients with allergic asthma[J]. Curr Pharm Des, 2019, 25(35): 3784-3795.
[12] Sellitto A, De Fanis U, Balestrieri A, et al. Effects of omalizumab treatment on serum cytokine concentrations of atopic patients with chronic spontaneous urticaria[J]. Eur Ann Allergy Clin Immunol, 2017, 49(4): 171-175.
[13] Minegishi Y, Saito M. Molecular mechanisms of the immunological abnormalities in hyper-IgE syndrome[J]. Ann N Y Acad Sci, 2011, 1246: 34-40.
[14] Knochelmann HM, Dwyer CJ, Bailey SR, et al. When worlds collide: Th17 and Treg cells in cancer and autoimmunity[J]. Cell Mol Immunol, 2018, 15(5): 458-469.
[15] Boonpiyathad T, S?zener ZC, Satitsuksanoa P, et al. Immunologic mechanisms in asthma[J]. Semin Immunol, 2019, 46: 101333.
[16] Ogawa R, Suzuki Y, Kagawa S, et al. Distinct effects of endogenous interleukin-23 on eosinophilic airway inflammation in response to different antigens[J]. Allergol Int, 2015, 64 Suppl: S24-S29.
[17] Moreira AP, Cavassani KA, Ismailoglu UB, et al. The protective role of TLR6 in a mouse model of asthma is mediated by IL-23 and IL-17A[J]. J Clin Invest, 2011, 121(11): 4420-4432.
[18] Djukanovi? R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma[J]. Am J Respir Crit Care Med, 2004, 170(6): 583-593.
[19] Noga O, Hanf G, Brachmann I, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma[J]. J Allergy Clin Immunol, 2006, 117(6): 1493-1499.
[20] Huang YC, Weng CM, Lee MJ, et al. Endotypes of severe allergic asthma patients who clinically benefit from anti-IgE therapy[J]. Clin Exp Allergy, 2019, 49(1): 44-53.
Options
Outlines

/

〈 〉